The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
Other factors such as state-level laws, insurance networks, or cultural preferences likely explain the remaining variance in brand preference across US counties, according to researchers Rachel D. Melamed, PhD, and Andrey Rzhetsky, PhD, of the University of Chicago. They concluded that a “patchwork” of contrasting medication cultures is in place across the nation, showing “geographically separated sub-Americas” that demonstrate the influences of racial composition, state-level healthcare laws, and wealth.
Their findings are based on an analysis of Truven MarketScan medical claims data covering more than 150 million individuals (nearly half the country’s population), followed for up to 10 years (2003-2013). The authors focused on comparing prescription rates of the 598 most highly prescribed drugs in more than 2300 US counties. The data contain a total of approximately 36 million patient-years.
Among the study’s findings are the following:
The study was funded by the DARPA Big Mechanism program and by National Institutes of Health grants.
Reference
Melamed RD, Rzhetsky A. Patchwork of contrasting medication cultures across the USA. Nature Communications.2018;9:4022. doi: 10.1038/s41467-018-06205-1.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.